small molecule

PEMAZYRE

PEMIGATINIB

Loss of exclusivityOctober 2040latest FDA-listed patent expiry

CompanyIncyte →See this company's full patent-cliff portfolio

Drug detail

Brand name	PEMAZYRE
Active ingredient	PEMIGATINIB
Strength	4.5MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12552792	October 2040	substance, product
11628162	August 2040	use U-3571
11466004	May 2039	use U-3466
9611267	January 2035	substance, product
10131667	April 2034	use U-2809

Regulatory exclusivity

Code	Expires
ODE-404	August 2029
ODE-292	April 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Incyte